Recent advances in cytokines in cutaneous and systemic lupus erythematosus

Journal of Dermatology

Volumn 38, Issue 9, 2011, Pages 839-849

  Mikita, Naoya ^a,b   Ikeda, Takaharu ^a   Ishiguro, Mariko ^a   Furukawa, Fukumi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Hashimoto Municipal Hospital   (Japan)

Author keywords

cutaneous lupus erythematosus; cytokine; erythematosus; systemic lupus

Indexed keywords

ALPHA INTERFERON; AMG 811; ANTIMALARIAL AGENT; AUTOANTIBODY; CHLOROQUINE; CYTOKINE; CYTOKINE RECEPTOR; ETANERCEPT; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RONTALIZUMAB; SIFALIMUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INFLAMMATION; KERATINOCYTE; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; NONHUMAN; PATHOGENESIS; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET IRRADIATION;

ANIMALS; CYTOKINES; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-18; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MODELS, IMMUNOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052057054     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01237.x     Document Type: Review

References (105)

1. Rahman A, Isenberg DA,. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-939. (Pubitemid 351397092)
2. Crispín JC, Liossis SN, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16: 47-57.
3. Elaine VL, Antonio LC,. Cytokines in systemic lupus erythematosus. Curr Mol Med 2009; 9: 242-254.
4. Lee HM, Sugino H, Nishimoto N,. Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol Published online: 15 April 2010; doi:.
5. Moser KL, Kelly JA, Lessard CJ, Harley JB,. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009; 10: 373-379.
6. Graham RR, Hom G, Ortmann W, Behrens TW,. Review of recent genome-wide association scans in lupus. J Intern Med 2009; 265: 680-688.
7. Rönnblom L, Elkon KB,. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6: 339-347.
8. Obermoser G, Sontheimer RD, Zelger B,. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010; 19: 1050-1070.
9. Tsuchida T,. Classification of lupus erythematosus based upon Japanese patients. Autoimmun Rev 2009; 8: 453-455.
10. Gilliam JN, Sontheimer RD,. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471-475. (Pubitemid 11094651)
11. Kuhn A, Bijl M,. Pathogenesis of cutaneous lupus erythematosus. Lupus 2008; 17: 389-393. (Pubitemid 351798714)
12. Ghoreishi M, Dutz JP,. Cutaneous lupus erythematosus: recent lessons from animal models. Lupus 2010; 19: 1029-1035.
13. Wenzel J, Zahn S, Tüting T,. Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. Lupus 2010; 19: 1020-1028.
14. Kalliolias GD, Ivashkiv LB,. Overview of the biology of type I interferons. Arthritis Res Ther 2010; 12 (Suppl. 1): S1.
15. Rönnblom L, Pascual V,. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17: 394-399. (Pubitemid 351798715)
16. Koutouzov S, Mathian A, Dalloul A,. Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 2006; 5: 554-562. (Pubitemid 44508854)
17. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788. (Pubitemid 36350872)
18. Ramanujam M, Kahn P, Huang W, et al. Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum 2009; 60: 1096-1101.
19. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S,. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174: 2499-2506. (Pubitemid 40279662)
20. Hron JD, Peng SL,. Type I IFN protects against murine lupus. J Immunol 2004; 173: 2134-2142. (Pubitemid 38971652)
21. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL,. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8. (Pubitemid 9226519)
22. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr,. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64: 1692-1697. (Pubitemid 41667141)
23. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615. (Pubitemid 36297546)
24. Crow MK, Kirou KA, Wohlgemuth J,. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003; 36: 481-490. (Pubitemid 37498244)
25. Gota C, Calabrese L,. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36: 511-518. (Pubitemid 37498247)
26. Meyer O,. Interferons and autoimmune disorders. Joint Bone Spine 2009; 76: 464-473.
27. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785-1796.
28. Yao Y, Higgs BW, Richman L, White B, Jallal B,. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010; 12 (Suppl 1): S6.
29. McBride JM, Wallace DJ, Yao Z, et al. Dose-dependent modulation of interferon regulated genes with administration of single and repeat doses of Rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE. Arthritis Rheum 2009; 60: S775-S776 (abstract 2072).
30. Wallace DJ, Petri M, Olsen N, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematous. Arthritis Rheum 2007; 56: S526-S527 (abstract 1325).
31. Wenzel J, Zahn S, Bieber T, Tüting T,. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch Dermatol Res 2009; 301: 83-86.
32. Wenzel J, Tüting T,. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol 2007; 16: 454-463. (Pubitemid 46585374)
33. Fäh J, Pavlovic J, Burg G,. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem 1995; 43: 47-52.
34. Wenzel J, Wörenkämper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005; 205: 435-442. (Pubitemid 40361331)
35. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL,. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159: 237-243. (Pubitemid 33704208)
36. Wenzel J, Zahn S, Mikus S, Wiechert A, Bieber T, Tüting T,. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol 2007; 157: 752-757. (Pubitemid 47389912)
37. Lövgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Rönnblom L,. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006; 54: 1917-1927. (Pubitemid 43877941)
38. Zahn S, Rehkämper C, Kümmerer BM, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN lambda) in cutaneous lupus erythematosus. J Invest Dermatol 2011; 131: 133-140.
39. Jacob CO, Van der Meide PH, McDevitt HO,. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987; 166: 798-803. (Pubitemid 18013554)
40. Haas C, Ryffel B, Le Hir M,. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol 1998; 160: 3713-3718. (Pubitemid 28176072)
41. Balomenos D, Rumold R, Theofilopoulos AN,. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998; 101: 364-371. (Pubitemid 28067333)
42. Seery JP, Carroll JM, Cattell V, Watt FM,. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med 1997; 186: 1451-1459. (Pubitemid 27479804)
43. al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S,. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993; 13: 58-67. (Pubitemid 23047997)
44. Akahoshi M, Nakashima H, Tanaka Y, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1644-1648. (Pubitemid 30263632)
45. Calvani N, Tucci M, Richards HB, Tartaglia P, Silvestris F,. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun Rev 2005; 4: 542-548. (Pubitemid 41415767)
46. Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N,. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 2008; 181: 2211-2219.
47. Uhm WS, Na K, Song GW, et al. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003; 42: 935-938. (Pubitemid 37220958)
48. Kirou KA, Crow MK,. New pieces to the SLE cytokine puzzle. Clin Immunol 1999; 91: 1-5.
49. Yoshimasu T, Nishide T, Seo N, et al. Susceptibility of T cell receptor-alpha chain knock-out mice to ultraviolet B light and fluorouracil: a novel model for drug-induced cutaneous lupus erythematosus. Clin Exp Immunol 2004; 136: 245-254. (Pubitemid 38543442)
50. Nishide T, Yoshimasu T, Ikeda T, Seo N, Ohtani T, Furukawa F,. Cytokine profiles of skin lesions in murine lupus models. J Dermatol Sci Suppl 2005; 1: S37-S43. (Pubitemid 47498256)
51. Kim CH, Rott L, Kunkel EJ, et al. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 2001; 108: 1331-1339. (Pubitemid 33107761)
52. Jacob CO, McDevitt HO,. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988; 331: 356-358. (Pubitemid 18042493)
53. Yokoyama H, Kreft B, Kelley VR,. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995; 47: 122-130.
54. Aringer M, Smolen JS,. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther. Published online: 23 January 2008; doi:.
55. Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS,. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274-279. (Pubitemid 46106201)
56. BÃ¥ve U, Vallin H, Alm GV, Rönnblom L,. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001; 17: 71-80. (Pubitemid 32751883)
57. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD,. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001; 167: 6821-6826. (Pubitemid 33144173)
58. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303-308. (Pubitemid 27104093)
59. Aringer M, Smolen JS,. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008; 7: 411-419.
60. Werth VP, Zhang W, Dortzbach K, Sullivan K,. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol 2000; 115: 726-730.
61. Maczynska I, Millo B, Ratajczak-Stefańska V, et al. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett 2006; 102: 79-82. (Pubitemid 41606043)
62. Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006; 65: 545-548.
63. Bashir MM, Sharma MR, Werth VP,. TNF-alpha production in the skin. Arch Dermatol Res 2009; 301: 87-91.
64. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ,. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009; 61: 486-504.
65. Hattori M, Nishide T, Yamanouchi K,. Cutaneous lupus erythematosus induced by etanercept. J Visual Dermatol 2010; 9: 840-841 (in Japanese).
66. Kishimoto T,. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-352.
67. Tackey E, Lipsky PE, Illei GG,. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13: 339-343. (Pubitemid 38788493)
68. Tang B, Matsuda T, Akira S, et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol 1991; 3: 273-278.
69. Suzuki H, Yasukawa K, Saito T, et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993; 23: 1078-1082. (Pubitemid 23120169)
70. Kobayashi I, Matsuda T, Saito T, et al. Abnormal distribution of IL-6 receptor in aged MRL/lpr mice: elevated expression on B cells and absence on CD4+ cells. Int Immunol 1992; 4: 1407-1412. (Pubitemid 23005958)
71. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ,. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 1994; 144: 927-937.
72. Finck BK, Chan B, Wofsy D,. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994; 94: 585-591. (Pubitemid 24250987)
73. Mihara M, Takagi N, Takeda Y, Ohsugi Y,. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998; 112: 397-402. (Pubitemid 28267419)
74. Gröndal G, Gunnarsson I, Rönnelid J, Rogberg S, Klareskog L, Lundberg I,. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18: 565-570.
75. Mellor-Pita S, Citores MJ, Castejon R, et al. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin Cytom 2009; 76B: 261-270.
76. Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007; 27: 461-466.
77. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542-552.
78. Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe DP, Sysa-Jedrzejowska A,. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol 2008; 159: 1124-1130.
79. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M,. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-310. (Pubitemid 24012996)
80. Yin Z, Bahtiyar G, Zhang N, et al. IL-10 regulates murine lupus. J Immunol 2002; 169: 2148-2155. (Pubitemid 34857682)
81. Blenman KR, Duan B, Xu Z, et al. IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest 2006; 86: 1136-1148. (Pubitemid 44624150)
82. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC,. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 393-395.
83. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH,. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 283-288. (Pubitemid 28219167)
84. Llorente L, Richaud-Patin Y, García-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790-1800.
85. Ivanov S, Lindén A,. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009; 30: 95-103.
86. Nalbandian A, Crispín JC, Tsokos GC,. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009; 157: 209-215.
87. Zhang Z, Kyttaris VC, Tsokos GC,. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009; 183: 3160-3169.
88. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW,. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. J Autoimmun 2008; 31: 79-89.
89. Yang J, Chu Y, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1472-1483.
90. Crispín JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181: 8761-8766.
91. Dong G, Ye R, Shi W, et al. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl) 2003; 116: 543-548. (Pubitemid 36675854)
92. Tanasescu C, Balanescu E, Balanescu P, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med 2010; 21: 202-207.
93. Gracie JA, Robertson SE, McInnes IB,. Interleukin-18. J Leukoc Biol 2003; 73: 213-224. (Pubitemid 36158296)
94. Esfandiari E, McInnes IB, Lindop G, et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol 2001; 167: 5338-5347. (Pubitemid 33009773)
95. Favilli F, Anzilotti C, Martinelli L, et al. IL-18 activity in systemic lupus erythematosus. Ann NY Acad Sci 2009; 1173: 301-309.
96. Bossù P, Neumann D, Del Giudice E, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA 2003; 100: 14181-14186. (Pubitemid 37499211)
97. Wong CK, Li EK, Ho CY, Lam CW,. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 1078-1081.
98. Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F,. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol 2004; 138: 171-178. (Pubitemid 39279981)
99. Amerio P, Frezzolini A, Abeni D, et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 2002; 20: 535-538. (Pubitemid 34846629)
100. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F,. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008; 58: 251-262.
101. Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM,. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun 2010; 34: 121-126.
102. Wang D, Drenker M, Eiz-Vesper B, Werfel T, Wittmann M,. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum 2008; 58: 3205-3215.
103. Werth VP, Bashir MM, Zhang W,. IL-12 completely blocks ultraviolet-induced secretion of tumor necrosis factor alpha from cultured skin fibroblasts and keratinocytes. J Invest Dermatol 2003; 120: 116-122. (Pubitemid 36120980)
104. Schwarz A, Maeda A, Kernebeck K, Van Steeg H, Beissert S, Schwarz T,. Prevention of UV radiation-induced immunosuppression by IL-12 is dependent on DNA repair. J Exp Med 2005; 201: 173-179. (Pubitemid 40189425)
105. Wittmann M, Macdonald A, Renne J,. IL-18 and skin inflammation. Autoimmun Rev 2009; 9: 45-48.